Teva Pharmaceutical Industries (NYSE:TEVA) Stock Rating Upgraded by StockNews.com

Teva Pharmaceutical Industries (NYSE:TEVA) was upgraded by StockNews.com from a “hold” rating to a “buy” rating in a report issued on Friday.

Several other equities research analysts have also commented on TEVA. UBS Group dropped their price target on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a research note on Thursday, January 30th. Piper Sandler raised their target price on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a research report on Friday, January 17th. Bank of America reduced their price target on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating for the company in a research report on Thursday, March 6th. Finally, Barclays lowered their price target on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a report on Thursday, January 30th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $23.43.

Teva Pharmaceutical Industries Trading Down 2.9 %

NYSE:TEVA opened at $14.85 on Friday. The firm has a market capitalization of $16.83 billion, a P/E ratio of -10.24, a P/E/G ratio of 1.44 and a beta of 0.82. The business has a 50 day simple moving average of $16.67 and a 200 day simple moving average of $18.04. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75. Teva Pharmaceutical Industries has a 12-month low of $12.51 and a 12-month high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. Equities research analysts predict that Teva Pharmaceutical Industries will post 2.5 EPS for the current year.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Several large investors have recently made changes to their positions in TEVA. FMR LLC lifted its stake in Teva Pharmaceutical Industries by 30.7% during the fourth quarter. FMR LLC now owns 81,983,231 shares of the company’s stock valued at $1,806,910,000 after purchasing an additional 19,242,468 shares during the last quarter. Clal Insurance Enterprises Holdings Ltd increased its holdings in shares of Teva Pharmaceutical Industries by 12.8% in the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 38,962,773 shares of the company’s stock valued at $859,935,000 after buying an additional 4,418,961 shares in the last quarter. Ion Asset Management Ltd. lifted its position in shares of Teva Pharmaceutical Industries by 1.1% during the 4th quarter. Ion Asset Management Ltd. now owns 36,650,000 shares of the company’s stock valued at $807,766,000 after acquiring an additional 409,778 shares during the last quarter. Lingotto Investment Management LLP boosted its stake in shares of Teva Pharmaceutical Industries by 2.6% during the 4th quarter. Lingotto Investment Management LLP now owns 27,192,388 shares of the company’s stock worth $599,320,000 after acquiring an additional 688,862 shares in the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. grew its holdings in shares of Teva Pharmaceutical Industries by 2.2% in the 4th quarter. Migdal Insurance & Financial Holdings Ltd. now owns 26,035,422 shares of the company’s stock worth $573,822,000 after acquiring an additional 569,412 shares during the last quarter. Institutional investors own 54.05% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.